<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791958</url>
  </required_header>
  <id_info>
    <org_study_id>FCD-PP-1501</org_study_id>
    <nct_id>NCT02791958</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy</brief_title>
  <official_title>Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the pharmacodynamics of a Fixed Dose Combination Pill AAR
      (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) and the respective
      reference products, atorvastatin (Lipitor®) 40 mg and ramipril (Altace®) 10 mg.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the adjusted mean 24-h systolic blood pressure results using ABPM between the baseline (week 0) and the final visit (week 8).</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in LDL cholesterol levels between the baseline (week 4) and the final visit (week 8).</measure>
    <time_frame>Measures at baseline visit (week 4) and final visit (week 8).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the adjusted mean 24-h diastolic blood pressure results (using ABPM) between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the adjusted mean 24-h mean arterial pressure results (using ABPM) between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the adjusted mean 24-h heart rate results (using ABPM) between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Very Low-Density Lipoprotein (VLDL) cholesterol levels between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in HDL cholesterol levels between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in total cholesterol levels between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in triglyceride levels between the basal and the final visits.</measure>
    <time_frame>Measures at baseline visit (week 0) and final visit (week 8).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through study completion, an average of 3 months.</time_frame>
    <description>AEs, clinical laboratory parameters (hematology, clinical chemistry, and urinalysis), vital signs, electrocardiogram (ECG), and physical examination.
The total number of patients with at least one AE and the number of AEs will be included in listings and tabulations. AEs will be coded using MedDRA, classified by system organ class (SOC) and preferred term and tabulated by intensity and causal relationship for each treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">528</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CV Fixed Dose Combination Pill AAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg (Lipitor®).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramipril 10 mg (Altace®).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cardiovascular Fixed Dose Combination Pill AAR</intervention_name>
    <description>A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.</description>
    <arm_group_label>CV Fixed Dose Combination Pill AAR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 mg</intervention_name>
    <description>A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril 10 mg</intervention_name>
    <description>A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥18 and &lt;75 years.

          -  Patients with Stage 1 (SBP/DBP: 140-159/90-99 mmHg) or Stage 2 (SBP/DBP: ≥160/≥100
             mmHg) hypertension, either untreated or after a wash out period.

          -  Patients with an LDL cholesterol level of ≥100 mg/dL and, either untreated or after
             the wash out period.

          -  Patients untreated with BP lowering and / or lipid lowering medication

          -  Patients treated with BP lowering and / or lipid lowering medication can be included
             if the medication can be safely withdrawn as per physician's judgment.

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Patients with a BMI of &gt; 35

          -  SBP &lt; 140 mmHg and DBP &lt; 90 mmHg

          -  Severe hypertension defined as SBP &gt; 180 mmHg and Diastolic Blood Pressure (DBP) &gt; 110
             mmHg

          -  LDL cholesterol level of &lt;100 mg/dL, either untreated or after the wash out period.

          -  Serum triglyceride concentration ≥400 mg/dL, either untreated or after the wash out
             period.

          -  Patients with a medical condition requiring the chronic pharmacological treatments
             listed below:

               -  Cytochrome P450 3A4 (CYP3A4) inhibitors (eg itraconazole, ketoconazole,
                  erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and
                  nefazodone).

               -  Non-steroidal anti-inflammatory drugs (NSAIDs).

               -  K-sparing diuretics.

               -  Lithium.

               -  Amiodarone and verapamil.

               -  Oral anticoagulants (eg, warfarin).

               -  Steroids.

               -  Digoxin.

               -  Gemfibrozil.

               -  Niacin.

               -  Potassium supplements.

               -  Cyclosporine.

               -  Danazol.

               -  Rifampicin.

          -  Evidence of any known clinically significant chronic disease

          -  Patients with renal impairment with Creatinine Clearance (CrCl) &lt; 40 mL/ min/ 1.73 m2

          -  Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN).

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x ULN.

          -  Total bilirubin ≥1.5 x ULN

          -  Medical history or evidence of drug or alcohol abuse.

          -  Medical history of gastrointestinal bleeding or gastroduodenal ulcer.

          -  Presence of secondary dyslipidemia.

          -  For patients on antihypertensive and/ or cholesterol lowering medication impossibility
             to withdraw it safely as per physician's judgment

          -  Previous coronary artery bypass graft (CABG).

          -  Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting
             stent.

          -  Presence of severe congestive heart failure (New York Heart Classification (NYHC) III
             IV).

          -  Prior history of stroke, Transient Ischemic Attack (TIA), Myocardial Infarction (MI),
             and cardiomyopathy with systolic dysfunction (prior documented Left Ventricular
             Ejection Fraction (LVEF) &lt; 40%)

          -  Aspirin induced asthma

          -  Previous intolerance and/or hypersensitivity to ACE inhibitors, statins and/or
             salicylates.

          -  Presence of unstable angina.

          -  Lab values other than specified out of the central laboratory normal range considered
             clinically significant.

          -  Patients and their partners not using effective contraception methods (i.e. intra
             uterine device (IUD) and condom or diaphragm with spermicide and condom) during the
             study and for at least one month thereafter, oral contraceptives are allowed.

          -  Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of
             the study (females only). All women must have a negative urine pregnancy test at the
             Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at
             least one year.

          -  Presence of mental illness limiting the capacity for self-care.

          -  Presence of major systemic illnesses: renal disease, liver disease, neurological or
             psychiatric disease.

          -  Participation, in the 30 days preceding enrolment into the study, in any other
             clinical study in which investigational or marketed drugs were employed.

          -  Any other medical condition that in the investigators opinion may interfere with the
             study procedures and/or evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Surowitz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Awareness, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Investigators, Inc</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infoshpere Clinical Research, Inc</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAB Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Therapeutics Corporation</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moonshine Research Center, Inc</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Clinical Research</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Clinical Research Center inc</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. John C. Gutleber Weight Loss, Beauty, and Family Practice</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Jupitor</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chappel Group Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Center</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Metabolic and Atherosclerosis Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America LA, LLC</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Einstein Clinical Research</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Punzi Medical Center</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cullen Research, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Trials Worldwide LLC</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deleon Research, PLLC</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician PrimeCare Research Institute, PLLC dba H</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chysalis Clinical Research</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

